Inventage Lab Inc. announced on the 14th that it will be participating in the '28th American Society for Gene and Cell Therapy (ASGCT 2025)' held in New Orleans, USA from May 13th to 17th, and will be exhibiting its next-generation gene therapy manufacturing platform 'IVL-GeneFluidic®' and research and process automation equipment 'HandyGene' at a solo booth.
ASGCT is an international conference attended by approximately 10,000 people from around the world in the field of gene and cell therapy, and is one of the major events for the global pharmaceutical and bio industry to check the latest technology and market trends. Through this conference, Inventage Lab plans to present its self-developed LNP-based integrated manufacturing system on the global stage for the first time, and to present its 'Gene to GMP' vision that links from the research stage to GMP production, and to focus on securing global partnerships.
The 'IVL-GeneFluidic®' being released this time is a microfluidic-based automation platform that can manufacture mRNA and lipid nanoparticles (LNP) with high precision and high reproducibility. It comprehensively supports process optimization, scale-up, and quality validation, and the related technology is implemented through 'HandyGene', an automation equipment independently developed by Inventage Lab. HandyGene is characterized by providing a single workflow from initial research to clinical and commercial production, thereby increasing process consistency and efficiency compared to existing gene therapy production methods.
Inventage Lab is carrying out many large-scale national R&D projects centered on the platform. Representative examples include the Ministry of Trade, Industry and Energy’s ‘Advanced Production of Vaccine Raw Materials’ project, the Ministry of Health and Welfare and the Korea Health Industry Development Institute’s ‘ARPA-H’ project, and the Korea Disease Control and Prevention Agency’s ‘Pandemic Response mRNA Vaccine Development’ project. Through these, they are conducting non-clinical research on next-generation infectious disease response vaccine technology and domestically producing LNP manufacturing technology.
A company official said, “Through this ASGCT participation, we expect to be able to strengthen our technological presence in the gene therapy CDMO market as we are introducing our automation-based LNP platform to the global market for the first time.” He added, “HandyGene is the core of a platform that can respond to the entire process beyond a simple research tool, and IVL-GeneFluidic® is positioned as a next-generation manufacturing technology that global bio companies are paying attention to.”
- See more related articles
You must be logged in to post a comment.